Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands

J Virol. 2019 Jan 4;93(2):e01813-18. doi: 10.1128/JVI.01813-18. Print 2019 Jan 15.

Abstract

Emergent strains of human norovirus seed pandemic waves of disease. These new strains have altered ligand binding and antigenicity characteristics. Study of viral variants isolated from immunosuppressed patients with long-term norovirus infection indicates that initial virus in vivo evolution occurs at the same antigenic sites as in pandemic strains. Here, cellular ligand binding and antigenicity of two cocirculating strains isolated from a patient with long-term norovirus infection were characterized. The isolated GII.4 viruses differed from previous strains and from each other at known blockade antibody epitopes. One strain had a unique sequence in epitope D, including loss of an insertion at residue 394, corresponding to a decreased relative affinity for carbohydrate ligands. Replacement of 394 with alanine or restoration of the contemporary strain epitope D consensus sequence STT improved ligand binding relative affinity. However, monoclonal antibody blockade of binding potency was only gained for the consensus sequence, not by the alanine insertion. In-depth study of unique changes in epitope D indicated that ligand binding, but not antibody blockade of ligand binding, is maintained despite sequence diversity, allowing escape from blockade antibodies without loss of capacity for binding cellular ligands.IMPORTANCE Human norovirus causes ∼20% of all acute gastroenteritis and ∼200,000 deaths per year, primarily in young children. Most epidemic and all pandemic waves of disease over the past 30 years have been caused by type GII.4 human norovirus strains. The capsid sequence of GII.4 strains is changing over time, resulting in viruses with altered ligand and antibody binding characteristics. The carbohydrate binding pocket of these strains does not vary over time. Here, utilizing unique viral sequences, we study how residues in GII.4 epitope D balance the dual roles of variable antibody binding site and cellular ligand binding stabilization domain, demonstrating that amino acid changes in epitope D can result in loss of antibody binding without ablating ligand binding. This flexibility in epitope D likely contributes to GII.4 strain persistence by both allowing escape from antibody-mediated herd immunity and maintenance of cellular ligand binding and infectivity.

Keywords: antibody neutralization; antigenic drift; blockade antibody; immunocompromised; norovirus; receptor binding; viral evolution.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Blocking / metabolism*
  • Antibodies, Viral / metabolism
  • Caliciviridae Infections / immunology*
  • Caliciviridae Infections / virology
  • Capsid Proteins / chemistry
  • Capsid Proteins / genetics*
  • Capsid Proteins / immunology
  • Child
  • Epitopes / genetics
  • Epitopes / immunology*
  • Feces / virology
  • Humans
  • INDEL Mutation*
  • Immunity, Herd
  • Ligands
  • Norovirus / genetics
  • Norovirus / immunology
  • Norovirus / isolation & purification*
  • Protein Binding

Substances

  • Antibodies, Blocking
  • Antibodies, Viral
  • Capsid Proteins
  • Epitopes
  • Ligands